• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

April 5, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials
World Health Organization chloroquine and hydroxychloroquine, Remdesivir, a combination of HIV drugs Lopinavir and Ritonavir and a combination of those drugs plus interferon-beta coronavirus (COVID-19) clinical trial initiated
Riovant gimsilumab SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS) completion of phase 1 trial
Apeiron Biologics AG APN01 severely infected COVID-19 patients initiation of phase 2 trial
Sanofi

Regeneron
Kevzara (sarilumab) patients hospitalized with severe COVID-19 initiation of second phase 2/3 trial
Other Trials
Zymeworks

BeiGene
ZW25 in combination with chemotherapy and tislelizumab first-line treatment for patients with metastatic HER2-positive breast cancer and metastatic HER2-positive gastroesophageal adenocarcinoma first patient dosed in phase 1b/2 trial
InMed Pharmaceuticals INM-755 cream epidermolysis bullosa completion of phase 1 trial
Chi-Med HMPL-453 advanced malignant mesothelioma initiation of phase 2 trial
Mimetogen Pharmaceuticals tavilermide dry eye disease completed enrollment in phase 3 trial
Onconova Therapeutics rigosertib patients with higher-risk myelodysplastic syndromes (MDS) who have progressed on, failed to respond to or relapsed after prior hypomethylating agent (HMA) therapy completion of patient enrollment in phase 3 trial
Oyster Point Therapeutics OC-01 nasal spray signs and symptoms of dry eye disease completed enrollment in phase 3 trial
Seres Therapeutics SER-109 recurrent Clostridium difficile infection completed enrollment in phase 3 trial
MEI Pharma ME-401 adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies Fast-Track designation granted by FDA
Ryvu Therapeutics SEL120 acute myeloid leukemia Orphan Drug designation granted by FDA
Agios Pharmaceuticals AG-946 hemolytic anemias IND approved by the FDA
AnHeart Therapeutics taletrectinib first-and second-line Non-Small Cell Lung Cancer (NSCLC) patients with ROS1 mutations and locally advanced or metastatic solid tumors with NTRK mutations IND clearance and Clinical Trial Authorization granted from Chinese drug evaluation agency (CDE)
Intellia Therapeutics

Novartis
CRISPR/Cas9-based engineered cell therapy sickle cell disease IND approved by FDA
Chipscreen Biosciences CS12192 autoimmune diseases and other related diseases IND approved by Center for Drug Evaluation, National Medical Products Administration of China
AstraZeneca Imfinzi (durvalumab) first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide) approved by the FDA
Eli Lilly Taltz (ixekizumab) injection pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy approved by the FDA for expanded indication
Rockwell Medical intravenous formulation of Triferic (Triferic AVNU) adult patients with hemodialysis-dependent chronic kidney disease approved by the FDA
Zoll Medical second-generation TherOx System (SuperSaturated Oxygen SSO2) Therapy reduction of heart muscle damage in “widowmaker” heart attack patients approved by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing